CollPlant Biotechnologies (CLGN) Enterprise Value (2017 - 2026)

CollPlant Biotechnologies has reported Enterprise Value for 10 years, with the latest figure at -$6.0 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value rose 97.68% year-over-year to -$6.0 million; the trailing twelve-month figure through Mar 2026 stood at -$6.0 million (up 97.68% YoY), and the FY2025 full-year result was -$5.9 million, up 97.83% from the prior year.
• Enterprise Value for Q1 2026 stood at -$6.0 million, roughly flat from -$5.9 million in the prior quarter.
• The five-year high for Enterprise Value was -$5.9 million in Q4 2025, with the low at -$267.7 million in Q3 2024.
• Historically, Enterprise Value has averaged -$103.0 million across 5 years, with a median of -$33.0 million in 2022.
• Annual changes were most pronounced in 2022 — Enterprise Value jumped 99.91% — and 2024, when it slumped 892.51%.
• CollPlant Biotechnologies' Enterprise Value stood at -$201.4 million in 2022, then jumped by 85.05% to -$30.1 million in 2023, then plunged by 763.34% to -$259.9 million in 2024, then soared by 97.71% to -$5.9 million in 2025, then dropped by 0.1% to -$6.0 million in 2026.
• The last three Enterprise Value figures came in at -$6.0 million (Q1 2026), -$5.9 million (Q4 2025), and -$11.9 million (Q3 2025), per Business Quant data.